PMID- 19263808
OWN - NLM
STAT- MEDLINE
DCOM- 20090406
LR  - 20221207
IS  - 0895-3988 (Print)
IS  - 0895-3988 (Linking)
VI  - 21
IP  - 6
DP  - 2008 Dec
TI  - Plasma homocysteine and gene polymorphisms associated with the risk of 
      hyperlipidemia in northern Chinese subjects.
PG  - 514-20
LID - 10.1016/S0895-3988(09)60011-8 [doi]
AB  - OBJECTIVE: To examine the relationship between occurrence of hyperlipidemia, 
      plasma homocysteine and polymorphisms of methylenetetra hydrofolate reductase 
      (MTHFR) gene and methionine synthase (MS) gene. METHODS: A total of 192 
      hyperlipidemia patients were selected and divided into hypercholesterolemia 
      group, hypertriglyceridemia group, and combined hyperlipidemia group. Another 208 
      normal individuals were selected as control. Total plasma homocysteine (tHcy) 
      concentration was measured by high-performance liquid chromatography (HPLC). 
      Lipid profiles were measured for all subjects. The polymorphisms of MTHFR gene 
      C677T and MS gene A2756G were analyzed by PCR-RFLP. RESULTS: The tHcy 
      concentration in the combined hyperlipidemia patients was significantly higher 
      than that in the control (15.95 micromol/L vs 13.43 micromol/L, P < 0.05). The 
      prevalence of hyperhomocysteinemia (HHcy) in the combined hyperlipidemia group 
      was significantly higher than that in the control (42.2% vs. 23.0%, P = 0.015), 
      with the odds ratio (OR) of 3.339 (95% CI: 1.260-8.849). The hyperlipidemia 
      patients with HHcy had a higher concentration of total cholesterol (TC) than that 
      in the normal tHcy patients (5.67 +/- 0.95 mmol/L vs. 5.47 +/- 0.92 mmol/L, 
      P=0.034). There was no significant difference in genotype or allele frequencies 
      of MTHFR C677T between the hyperlipidemic and control groups. The hyperlipidemia 
      patients with MTHFR CT/TT genotype had a higher concentration of triglyceride 
      (TG) than those with CC genotype (2.24 +/- 1.75 mmol/L vs 1.87 +/- 0.95 mmol/L, P 
      < 0.05). Individuals with CT/TT genotype had a higher concentration of tHcy than 
      those with 677CC genotype both in the hyperlipidemia group (12.61 +/- 1.24 
      micromol/L vs. 11.20 +/- 1.37 micromol/L, P < 0.05) and in the control group 
      (14.04 +/- 1.48 micromol/L vs. 12.61 +/- 1.24 micromol/L, P < 0.05). The 
      percentage of MS 2756 GG/AG genotype in the combined hyperlipidemia group was 
      significantly higher than that in the control (26.7% vs. 13.0%, P = 0.012), with 
      the OR of 3.121 (95% CI: 1.288-7.651). The hyperlipidemia patients with MS 
      2756AG/GG genotype had a higher concentration of TC (5.87 +/- 0.89 mmol/L vs. 
      5.46 +/- 0.93 mmol/L, P < 0.05) and LDL-C (3.29 +/- 0.81 mmol/L vs. 2.94 +/- 0.85 
      mmol/L, P < 0.05) than those with AA genotype. However, individuals with 
      2756AG/GG genotype showed no significant difference in tHcy among those with AA 
      genotype. CONCLUSION: HHcy and MS A2756G mutation may be the risk factors for 
      combined hyperlipidemia. Further study is needed to confirm the role of HHcy and 
      MS A2756G mutation in the development of hyperlipidemia.
FAU - Huang, Lei
AU  - Huang L
AD  - Department of Nutrition and Food Hygiene, School of Public Health, Peking 
      University, Beijing 100083, China.
FAU - Song, Xiao-Ming
AU  - Song XM
FAU - Zhu, Wen-li
AU  - Zhu WL
FAU - Li, Yong
AU  - Li Y
LA  - eng
PT  - Journal Article
PT  - Research Support, Non-U.S. Gov't
PL  - China
TA  - Biomed Environ Sci
JT  - Biomedical and environmental sciences : BES
JID - 8909524
RN  - 0 (Lipids)
RN  - 0LVT1QZ0BA (Homocysteine)
RN  - EC 1.5.1.20 (Methylenetetrahydrofolate Reductase (NADPH2))
RN  - EC 2.1.1.13 (5-Methyltetrahydrofolate-Homocysteine S-Methyltransferase)
SB  - IM
MH  - 5-Methyltetrahydrofolate-Homocysteine S-Methyltransferase/*genetics
MH  - Asian People/*genetics
MH  - Base Sequence
MH  - Case-Control Studies
MH  - Female
MH  - Genotype
MH  - Homocysteine/*blood/metabolism
MH  - Humans
MH  - Hyperhomocysteinemia/blood/genetics/pathology
MH  - Hyperlipidemias/*blood/*genetics/pathology
MH  - Lipids/blood/genetics
MH  - Male
MH  - Methylenetetrahydrofolate Reductase (NADPH2)/*genetics
MH  - Middle Aged
MH  - *Polymorphism, Genetic
MH  - Risk Factors
EDAT- 2009/03/07 09:00
MHDA- 2009/04/07 09:00
CRDT- 2009/03/07 09:00
PHST- 2009/03/07 09:00 [entrez]
PHST- 2009/03/07 09:00 [pubmed]
PHST- 2009/04/07 09:00 [medline]
AID - S0895-3988(09)60011-8 [pii]
AID - 10.1016/S0895-3988(09)60011-8 [doi]
PST - ppublish
SO  - Biomed Environ Sci. 2008 Dec;21(6):514-20. doi: 10.1016/S0895-3988(09)60011-8.